{
  "hash": "f4783e72766b655b5c7cfb3a50dc1aaa",
  "result": {
    "engine": "knitr",
    "markdown": "---\ntitle: Development and Validation of a Risk Prediction Model of linezolid-induced thrombocytopenia in Vietnamese patients\n\n# authors:\n#   - name: Norah Jones\n#     affiliation: The University\n#     roles: writing\n#     corresponding: true\n# bibliography: references.bib\n\ncss: styles.css\n\nabstract: |\n  Write abstract here,\n  note the indentation\n---\n\n\n\n\n\n# Checklist\n\n| **Section/topic**                   | **Item No** | **Description**                                                                                                                                                                                                                       | **Page No** |\n|-------------------------------------|:-----------:|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:-----------:|\n| **Title and abstract**              |             |                                                                                                                                                                                                                                       |             |\n| Title                               |      1      | Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted                                                                                           |             |\n| Abstract                            |      2      | Provide a summary of research objectives, setting, participants, data source, sample size, predictors, outcome, statistical analysis, results, and conclusions*                                                                       |             |\n| **Introduction**                    |             |                                                                                                                                                                                                                                       |             |\n| Background and objectives           |      3a     | Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the prediction model, including references to existing models, and the advantages of the study design*            |             |\n|                                     |      3b     | Specify the objectives, including whether the study describes the development or validation of the model*                                                                                                                             |             |\n| **Methods**                         |             |                                                                                                                                                                                                                                       |             |\n| Participants and data               |      4a     | Describe eligibility criteria for participants and datasets*                                                                                                                                                                          |             |\n|                                     |      4b     | Describe the origin of the data, and how the data were identified, requested, and collected                                                                                                                                           |             |\n| Sample size                         |      5      | Explain how the sample size was arrived at*                                                                                                                                                                                           |             |\n| Outcomes and predictors             |      6a     | Define the outcome that is predicted by the model, including how and when assessed*                                                                                                                                                   |             |\n|                                     |      6b     | Define all predictors used in developing or validating the model, including how and when measured*                                                                                                                                    |             |\n| Data preparation                    |      7a     | Describe how the data were prepared for analysis, including any cleaning, harmonisation, linkage, and quality checks                                                                                                                  |             |\n|                                     |      7b     | Describe the method for assessing risk of bias and applicability in the individual clusters (eg, using PROBAST)                                                                                                                       |             |\n|                                     |      7c     | For validation, identify any differences in definition and measurement from the development data (eg, setting, eligibility criteria, outcome, predictors)*                                                                            |             |\n|                                     |      7d     | Describe how missing data were handled*                                                                                                                                                                                               |             |\n| Data analysis                       |      8a     | Describe how predictors were handled in the analyses                                                                                                                                                                                  |             |\n|                                     |      8b     | Specify the type of model, all model building procedures (eg, any predictor selection and penalisation), and method for validation*                                                                                                   |             |\n|                                     |      8c     | Describe how any heterogeneity across clusters (eg, studies or settings) in model parameter values was handled                                                                                                                        |             |\n|                                     |      8d     | For validation, describe how the predictions were calculated                                                                                                                                                                          |             |\n|                                     |      8e     | Specify all measures used to assess model performance (eg, calibration, discrimination, and decision curve analysis) and, if relevant, to compare multiple models                                                                     |             |\n|                                     |      8f     | Describe how any heterogeneity across clusters (eg, studies or settings) in model performance was handled and quantified                                                                                                              |             |\n|                                     |      8g     | Describe any model updating (eg, recalibration) arising from the validation, either overall or for particular populations or settings*                                                                                                |             |\n| Sensitivity analysis                |      9      | Describe any planned subgroup or sensitivity analysis—eg, assessing performance according to sources of bias, participant characteristics, setting                                                                                    |             |\n| **Results**                         |             |                                                                                                                                                                                                                                       |             |\n| Participants and datasets           |     10a     | Describe the number of clusters and participants from data identified through to data analysed; a flowchart might be helpful*                                                                                                         |             |\n|                                     |     10b     | Report the characteristics overall and where applicable for each data source or setting, including the key dates, predictors, treatments received, sample size, number of outcome events, follow-up time, and amount of missing data* |             |\n|                                     |     10c     | For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors, and outcome)                                                                                        |             |\n| Risk of bias                        |      11     | Report the results of the risk-of-bias assessment in the individual clusters                                                                                                                                                          |             |\n| Model development and specification |     12a     | Report the results of any assessments of heterogeneity across clusters that led to subsequent actions during the model’s development (eg, inclusion or exclusion of particular predictors or clusters)                                |             |\n|                                     |     12b     | Present the final prediction model (ie, all regression coefficients, and model intercept or baseline estimate of the outcome at a given time point) and explain how to use it for predictions in new individuals*                     |             |\n| Model performance                   |     13a     | Report performance measures (with uncertainty intervals) for the prediction model, overall and for each cluster                                                                                                                       |             |\n|                                     |     13b     | Report results of any heterogeneity across clusters in model performance                                                                                                                                                              |             |\n| Model updating                      |      14     | Report the results from any model updating (including the updated model equation and subsequent performance), overall and for each cluster*                                                                                           |             |\n| Sensitivity analysis                |      15     | Report results from any subgroup or sensitivity analysis                                                                                                                                                                              |             |\n| **Discussion**                      |             |                                                                                                                                                                                                                                       |             |\n| Interpretation                      |     16a     | Give an overall interpretation of the main results, including heterogeneity across clusters in model performance, in the context of the objectives and previous studies*                                                              |             |\n|                                     |     16b     | For validation, discuss the results with reference to the model performance in the development data, and in any previous validations                                                                                                  |             |\n|                                     |     16c     | Discuss the strengths of the study and any limitations (eg, missing or incomplete data, non-representativeness, data harmonisation problems)                                                                                          |             |\n| Implications                        |      17     | Discuss the potential use of the model and implications for future research, with specific view to generalisability and applicability of the model across different settings or (sub)populations                                      |             |\n| **Other information**               |             |                                                                                                                                                                                                                                       |             |\n| Supplementary information           |      18     | Provide information about the availability of supplementary resources (eg, study protocol, analysis code, datasets)*                                                                                                                  |             |\n| Funding                             |      19     | Give the source of funding and the role of the funders for the present study                                                                                                                                                          |             |\n\n: TRIPOD-Cluster checklist of items to include when reporting a study developing or validating a multivariable prediction model using clustered data {tbl-colwidths = \"[20, 10, 60, 10]\"}\n\n# Introduction\n## Background and objectives\n# Methods\n## Participants and data\n## Sample size\n\nThere are [number] candidate predictors selected by clinical experts, and the BMS algorithm identified [number] additional predictors, for a total of [number] predictors. \n\n## Outcomes and predictors\n## Data preparation\n## Data analysis\n## Sensitivity analysis\n# Results\n## Participants and datasets\n## Risk of bias\n## Model development and specification\n## Model performance\n## Model updating\n## Sensitivity analysis\n# Discussion\n## Interpretation\n## Implications\n# Other information\n## Supplementary information\n## Funding\n\n## Objectives\n1. Investigating risk factors of linezolid-induced thrombocytopenia (LI-TP)\n2. Developing and validating a logistics regression model to predict LI-TP in Vietnamese patients\n\n## Data cleaning\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\nsource(\"notebooks/initialize-data-analysis.r\")\n```\n\n::: {.cell-output .cell-output-stderr .hidden}\n\n```\n-- Attaching core tidyverse packages ------------------------ tidyverse 2.0.0 --\nv dplyr     1.1.4     v readr     2.1.5\nv forcats   1.0.0     v stringr   1.5.1\nv ggplot2   3.5.0     v tibble    3.2.1\nv lubridate 1.9.3     v tidyr     1.3.1\nv purrr     1.0.2     \n-- Conflicts ------------------------------------------ tidyverse_conflicts() --\nx dplyr::filter() masks stats::filter()\nx dplyr::lag()    masks stats::lag()\ni Use the conflicted package (<http://conflicted.r-lib.org/>) to force all conflicts to become errors\n```\n\n\n:::\n:::\n\n\n\n\n\n:::{.scrolling}\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\ndata_patient_complete |> select(all_of(predictor_list), flag_ADR_TP_ID, site) |> glimpse()\n```\n\n::: {.cell-output .cell-output-stdout}\n\n```\nRows: 816\nColumns: 58\n$ patient_age          <dbl> 90, 80, 79, 71, 72, 61, 60, 64, 92, 75, 86, 93, 6~\n$ patient_sex          <lgl> TRUE, TRUE, FALSE, FALSE, TRUE, FALSE, FALSE, TRU~\n$ LZD_dose_per_weight  <dbl> 25.00000, 30.00000, 30.00000, 13.33333, 17.14286,~\n$ baseline_CLCR        <dbl> 27.22860, 63.15805, 29.93031, 50.89929, 10.87932,~\n$ dept_ER              <lgl> TRUE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, T~\n$ dept_ICU             <lgl> FALSE, TRUE, TRUE, TRUE, TRUE, TRUE, TRUE, FALSE,~\n$ baseline_HGB         <dbl> 96, 101, 86, 94, 86, 99, 98, 119, 60, 118, 99, 10~\n$ baseline_WBC         <dbl> 6.75, 11.91, 14.05, 14.61, 7.92, 21.79, 13.27, 6.~\n$ baseline_PLT         <dbl> 244, 180, 259, 179, 236, 113, 196, 154, 147, 101,~\n$ LZD_duration         <dbl> 6, 8, 15, 3, 7, 8, 22, 4, 3, 16, 14, 7, 13, 20, 6~\n$ invasive_ETI         <lgl> FALSE, FALSE, FALSE, TRUE, TRUE, FALSE, TRUE, FAL~\n$ invasive_CVC         <lgl> FALSE, FALSE, TRUE, FALSE, TRUE, FALSE, TRUE, FAL~\n$ invasive_IHD         <lgl> FALSE, FALSE, FALSE, FALSE, TRUE, FALSE, FALSE, F~\n$ invasive_CRRT        <lgl> FALSE, FALSE, FALSE, TRUE, FALSE, FALSE, FALSE, F~\n$ comorb_HTN           <lgl> TRUE, TRUE, TRUE, TRUE, TRUE, FALSE, FALSE, TRUE,~\n$ comorb_DM            <lgl> TRUE, FALSE, FALSE, FALSE, TRUE, TRUE, FALSE, FAL~\n$ comorb_HF            <lgl> FALSE, TRUE, TRUE, TRUE, TRUE, FALSE, FALSE, TRUE~\n$ comorb_angina        <lgl> FALSE, TRUE, TRUE, FALSE, FALSE, FALSE, FALSE, FA~\n$ comorb_cirr          <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, TRUE, FALSE, F~\n$ comorb_COPD          <lgl> FALSE, FALSE, FALSE, TRUE, FALSE, FALSE, FALSE, F~\n$ comorb_CVA           <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comorb_MI            <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comorb_K             <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, TRUE, F~\n$ comorb_hematological <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comorb_hema          <lgl> FALSE, FALSE, FALSE, TRUE, FALSE, FALSE, FALSE, F~\n$ infect_sepsis        <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, TRUE, TRUE, TR~\n$ infect_CAP           <lgl> FALSE, FALSE, TRUE, FALSE, FALSE, FALSE, FALSE, F~\n$ infect_HAP           <lgl> TRUE, FALSE, FALSE, TRUE, TRUE, FALSE, FALSE, TRU~\n$ infect_SSTI          <lgl> FALSE, FALSE, FALSE, FALSE, TRUE, FALSE, FALSE, T~\n$ infect_CNS           <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, TRUE, FALSE, F~\n$ infect_IAI           <lgl> FALSE, TRUE, FALSE, FALSE, FALSE, TRUE, TRUE, FAL~\n$ infect_UTI           <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ infect_BJI           <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ infect_septicemia    <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comed_aspirin        <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comed_diclofenac     <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comed_ibuprofen      <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comed_paracetamol    <lgl> TRUE, TRUE, FALSE, FALSE, TRUE, TRUE, TRUE, TRUE,~\n$ comed_penicillin     <lgl> FALSE, TRUE, TRUE, TRUE, TRUE, FALSE, TRUE, FALSE~\n$ comed_cepha          <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, TRUE, FALSE, F~\n$ comed_carbapenem     <lgl> TRUE, TRUE, TRUE, FALSE, TRUE, TRUE, TRUE, TRUE, ~\n$ comed_cotrimoxazol   <lgl> FALSE, TRUE, FALSE, FALSE, FALSE, FALSE, FALSE, F~\n$ comed_vancomycin     <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comed_levofloxacin   <lgl> FALSE, FALSE, FALSE, FALSE, TRUE, FALSE, FALSE, F~\n$ comed_teicoplanin    <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comed_ethambutol     <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comed_pyrazinamid    <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comed_rifampin       <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comed_heparin        <lgl> FALSE, FALSE, FALSE, TRUE, TRUE, FALSE, FALSE, FA~\n$ comed_clopidogrel    <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comed_enoxaparin     <lgl> FALSE, FALSE, TRUE, TRUE, FALSE, TRUE, TRUE, FALS~\n$ comed_dexamethason   <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, TRUE, FALSE, F~\n$ comed_amiodaron      <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comed_furosemid      <lgl> FALSE, TRUE, TRUE, TRUE, TRUE, TRUE, TRUE, FALSE,~\n$ comed_haloperidol    <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ comed_valproic       <lgl> FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE, ~\n$ flag_ADR_TP_ID       <lgl> FALSE, FALSE, FALSE, FALSE, TRUE, TRUE, TRUE, FAL~\n$ site                 <chr> \"TN1\", \"TN1\", \"TN1\", \"TN1\", \"TN1\", \"TN1\", \"TN1\", ~\n```\n\n\n:::\n:::\n\n\n\n\n\n:::\n\n## Descriptive statistics\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\nload(\"data/results/table-descriptive.rda\")\n```\n:::\n\n\n\n\n\n:::{.scrolling}\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\ntable_descriptive\n```\n\n::: {.cell-output .cell-output-stderr .hidden}\n\n```\nTable printed with `knitr::kable()`, not {gt}. Learn why at\nhttps://www.danieldsjoberg.com/gtsummary/articles/rmarkdown.html\nTo suppress this message, include `message = FALSE` in code chunk header.\n```\n\n\n:::\n\n::: {.cell-output-display}\n\n\n|**Characteristic**       | **Overall**, N = 816 | **FALSE**, N = 552 | **TRUE**, N = 264  | **OR** | **95% CI** | **p-value** |\n|:------------------------|:--------------------:|:------------------:|:------------------:|:------:|:----------:|:-----------:|\n|__patient_age__          |     62 (50 - 73)     |    61 (47 - 72)    |    64 (54 - 74)    |  1.02  | 1.01, 1.03 | __<0.001__  |\n|__patient_sex__          |      306 (38%)       |     206 (37%)      |     100 (38%)      |  1.02  | 0.76, 1.38 |     0.9     |\n|__LZD_dose_per_weight__  |  21.8 (20.0 - 24.0)  | 21.8 (20.0 - 24.0) | 21.8 (19.4 - 24.6) |  0.99  | 0.96, 1.03 |     0.8     |\n|__baseline_CLCR__        |     48 (21 - 84)     |    55 (26 - 88)    |    32 (15 - 64)    |  0.99  | 0.99, 0.99 | __<0.001__  |\n|__dept_ER__              |      140 (17%)       |      95 (17%)      |      45 (17%)      |  0.99  | 0.67, 1.45 |    >0.9     |\n|__dept_ICU__             |      390 (48%)       |     240 (43%)      |     150 (57%)      |  1.71  | 1.27, 2.30 | __<0.001__  |\n|__baseline_HGB__         |    102 (89 - 120)    |   105 (91 - 121)   |   98 (85 - 117)    |  0.99  | 0.98, 0.99 | __<0.001__  |\n|__baseline_WBC__         |     12 (8 - 17)      |    12 (8 - 17)     |    12 (8 - 18)     |  1.01  | 0.99, 1.03 |     0.2     |\n|__baseline_PLT__         |   206 (143 - 288)    |  234 (167 - 309)   |  154 (103 - 211)   |  0.99  | 0.99, 0.99 | __<0.001__  |\n|__LZD_duration__         |   9.0 (6.0 - 14.0)   |  9.0 (6.0 - 13.0)  | 10.0 (6.0 - 14.0)  |  1.03  | 1.01, 1.06 |  __0.017__  |\n|__invasive_ETI__         |      386 (47%)       |     230 (42%)      |     156 (59%)      |  2.02  | 1.50, 2.73 | __<0.001__  |\n|__invasive_CVC__         |      423 (52%)       |     246 (45%)      |     177 (67%)      |  2.53  | 1.87, 3.45 | __<0.001__  |\n|__invasive_IHD__         |      111 (14%)       |      64 (12%)      |      47 (18%)      |  1.65  | 1.09, 2.48 |  __0.016__  |\n|__invasive_CRRT__        |      147 (18%)       |      64 (12%)      |      83 (31%)      |  3.50  | 2.42, 5.07 | __<0.001__  |\n|__comorb_HTN__           |      333 (41%)       |     218 (39%)      |     115 (44%)      |  1.18  | 0.88, 1.59 |     0.3     |\n|__comorb_DM__            |      222 (27%)       |     150 (27%)      |      72 (27%)      |  1.01  | 0.72, 1.39 |    >0.9     |\n|__comorb_HF__            |      225 (28%)       |     131 (24%)      |      94 (36%)      |  1.78  | 1.29, 2.44 | __<0.001__  |\n|__comorb_angina__        |      32 (3.9%)       |     19 (3.4%)      |     13 (4.9%)      |  1.45  | 0.69, 2.96 |     0.3     |\n|__comorb_cirr__          |      48 (5.9%)       |     20 (3.6%)      |      28 (11%)      |  3.16  | 1.75, 5.79 | __<0.001__  |\n|__comorb_COPD__          |      39 (4.8%)       |     25 (4.5%)      |     14 (5.3%)      |  1.18  | 0.59, 2.28 |     0.6     |\n|__comorb_CVA__           |       93 (11%)       |      64 (12%)      |      29 (11%)      |  0.94  | 0.58, 1.49 |     0.8     |\n|__comorb_MI__            |      20 (2.5%)       |     15 (2.7%)      |      5 (1.9%)      |  0.69  | 0.22, 1.81 |     0.5     |\n|__comorb_K__             |      67 (8.2%)       |     44 (8.0%)      |     23 (8.7%)      |  1.10  | 0.64, 1.85 |     0.7     |\n|__comorb_hematological__ |      46 (5.6%)       |     27 (4.9%)      |     19 (7.2%)      |  1.51  | 0.81, 2.75 |     0.2     |\n|__comorb_hema__          |      61 (7.5%)       |     37 (6.7%)      |     24 (9.1%)      |  1.39  | 0.81, 2.36 |     0.2     |\n|__infect_sepsis__        |      134 (16%)       |      66 (12%)      |      68 (26%)      |  2.55  | 1.75, 3.73 | __<0.001__  |\n|__infect_CAP__           |      118 (14%)       |      70 (13%)      |      48 (18%)      |  1.53  | 1.02, 2.28 |  __0.038__  |\n|__infect_HAP__           |      375 (46%)       |     255 (46%)      |     120 (45%)      |  0.97  | 0.72, 1.30 |     0.8     |\n|__infect_SSTI__          |      133 (16%)       |     100 (18%)      |      33 (13%)      |  0.65  | 0.42, 0.98 |  __0.043__  |\n|__infect_CNS__           |      68 (8.3%)       |     46 (8.3%)      |     22 (8.3%)      |  1.00  | 0.58, 1.68 |    >0.9     |\n|__infect_IAI__           |      50 (6.1%)       |     34 (6.2%)      |     16 (6.1%)      |  0.98  | 0.52, 1.79 |    >0.9     |\n|__infect_UTI__           |      53 (6.5%)       |     37 (6.7%)      |     16 (6.1%)      |  0.90  | 0.48, 1.62 |     0.7     |\n|__infect_BJI__           |      11 (1.3%)       |     10 (1.8%)      |      1 (0.4%)      |  0.21  | 0.01, 1.08 |    0.13     |\n|__infect_septicemia__    |      237 (29%)       |     148 (27%)      |      89 (34%)      |  1.39  | 1.01, 1.90 |  __0.043__  |\n|__comed_aspirin__        |      47 (5.8%)       |     30 (5.4%)      |     17 (6.4%)      |  1.20  | 0.64, 2.19 |     0.6     |\n|__comed_diclofenac__     |      27 (3.3%)       |     20 (3.6%)      |      7 (2.7%)      |  0.72  | 0.28, 1.66 |     0.5     |\n|__comed_ibuprofen__      |      26 (3.2%)       |     15 (2.7%)      |     11 (4.2%)      |  1.56  | 0.69, 3.42 |     0.3     |\n|__comed_paracetamol__    |      357 (44%)       |     246 (45%)      |     111 (42%)      |  0.90  | 0.67, 1.21 |     0.5     |\n|__comed_penicillin__     |      123 (15%)       |      78 (14%)      |      45 (17%)      |  1.25  | 0.83, 1.86 |     0.3     |\n|__comed_cepha__          |      208 (25%)       |     150 (27%)      |      58 (22%)      |  0.75  | 0.53, 1.06 |    0.11     |\n|__comed_carbapenem__     |      588 (72%)       |     385 (70%)      |     203 (77%)      |  1.44  | 1.03, 2.04 |  __0.034__  |\n|__comed_cotrimoxazol__   |      67 (8.2%)       |     39 (7.1%)      |      28 (11%)      |  1.56  | 0.93, 2.59 |    0.087    |\n|__comed_vancomycin__     |      67 (8.2%)       |     41 (7.4%)      |     26 (9.8%)      |  1.36  | 0.81, 2.27 |     0.2     |\n|__comed_levofloxacin__   |      250 (31%)       |     162 (29%)      |      88 (33%)      |  1.20  | 0.88, 1.65 |     0.2     |\n|__comed_teicoplanin__    |      37 (4.5%)       |     23 (4.2%)      |     14 (5.3%)      |  1.29  | 0.64, 2.52 |     0.5     |\n|__comed_ethambutol__     |       8 (1.0%)       |      5 (0.9%)      |      3 (1.1%)      |  1.26  | 0.26, 5.16 |     0.8     |\n|__comed_pyrazinamid__    |      12 (1.5%)       |      6 (1.1%)      |      6 (2.3%)      |  2.12  | 0.66, 6.83 |     0.2     |\n|__comed_rifampin__       |      15 (1.8%)       |      8 (1.4%)      |      7 (2.7%)      |  1.85  | 0.64, 5.21 |     0.2     |\n|__comed_heparin__        |      207 (25%)       |     109 (20%)      |      98 (37%)      |  2.40  | 1.73, 3.33 | __<0.001__  |\n|__comed_clopidogrel__    |      40 (4.9%)       |     30 (5.4%)      |     10 (3.8%)      |  0.69  | 0.31, 1.38 |     0.3     |\n|__comed_enoxaparin__     |      352 (43%)       |     235 (43%)      |     117 (44%)      |  1.07  | 0.80, 1.44 |     0.6     |\n|__comed_dexamethason__   |      106 (13%)       |      72 (13%)      |      34 (13%)      |  0.99  | 0.63, 1.51 |    >0.9     |\n|__comed_amiodaron__      |      36 (4.4%)       |     17 (3.1%)      |     19 (7.2%)      |  2.44  | 1.24, 4.82 |  __0.009__  |\n|__comed_furosemid__      |      436 (53%)       |     260 (47%)      |     176 (67%)      |  2.25  | 1.66, 3.06 | __<0.001__  |\n|__comed_haloperidol__    |      53 (6.5%)       |     36 (6.5%)      |     17 (6.4%)      |  0.99  | 0.53, 1.76 |    >0.9     |\n|__comed_valproic__       |      32 (3.9%)       |     23 (4.2%)      |      9 (3.4%)      |  0.81  | 0.35, 1.72 |     0.6     |\n|__comed_aceclofenac__    |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_naproxen__       |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_daptomycin__     |       1 (0.1%)       |       0 (0%)       |      1 (0.4%)      |        |            |             |\n|__comed_cetirizin__      |       6 (0.7%)       |      5 (0.9%)      |      1 (0.4%)      |        |            |             |\n|__comed_simvas__         |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_bisoprolol__     |       6 (0.7%)       |      4 (0.7%)      |      2 (0.8%)      |        |            |             |\n|__comed_diltiazem__      |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_eptifibatid__    |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_quinidin__       |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_carbamazepin__   |       8 (1.0%)       |      8 (1.4%)      |       0 (0%)       |        |            |             |\n|__comed_phenytoin__      |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_mirtazapin__     |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_quetiapin__      |       4 (0.5%)       |      4 (0.7%)      |       0 (0%)       |        |            |             |\n|__comed_ondansetron__    |       6 (0.7%)       |      4 (0.7%)      |      2 (0.8%)      |        |            |             |\n|__comed_palonosetron__   |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_oseltamivir__    |       2 (0.2%)       |      1 (0.2%)      |      1 (0.4%)      |        |            |             |\n|__comed_quinin__         |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_pembrolizumab__  |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_trastuzumab__    |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_atezolizumab__   |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_durvalumab__     |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_IVIG__           |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_tacrolimus__     |       1 (0.1%)       |       0 (0%)       |      1 (0.4%)      |        |            |             |\n|__comed_fluorouracil__   |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_irinotecan__     |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_leucovorin__     |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n|__comed_oxaliplatin__    |        0 (0%)        |       0 (0%)       |       0 (0%)       |        |            |             |\n\n\n:::\n:::\n\n\n\n\n\n:::\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\nload(\"data/results/table-descriptive-site.rda\")\n```\n:::\n\n\n\n\n\n:::{.scrolling}\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\ntable_descriptive_site\n```\n\n::: {.cell-output .cell-output-stderr .hidden}\n\n```\nTable printed with `knitr::kable()`, not {gt}. Learn why at\nhttps://www.danieldsjoberg.com/gtsummary/articles/rmarkdown.html\nTo suppress this message, include `message = FALSE` in code chunk header.\n```\n\n\n:::\n\n::: {.cell-output-display}\n\n\n|**Characteristic**       | **Overall**, N = 816 |  **BM1**, N = 125  |  **BM2**, N = 77   |  **ND1**, N = 179  |  **ND2**, N = 116  |  **TN1**, N = 100  |  **TN2**, N = 219  | **p-value** |\n|:------------------------|:--------------------:|:------------------:|:------------------:|:------------------:|:------------------:|:------------------:|:------------------:|:-----------:|\n|__patient_age__          |     62 (50 - 73)     |    58 (43 - 69)    |    60 (45 - 72)    |    60 (45 - 68)    |    59 (46 - 68)    |    69 (60 - 78)    |    66 (58 - 78)    | __<0.001__  |\n|__patient_sex__          |      306 (38%)       |      54 (43%)      |      27 (35%)      |      73 (41%)      |      28 (24%)      |      48 (48%)      |      76 (35%)      |  __0.004__  |\n|__LZD_dose_per_weight__  |  21.8 (20.0 - 24.0)  | 22.6 (20.0 - 25.5) | 21.4 (19.0 - 24.0) | 21.4 (19.4 - 24.0) | 21.8 (20.0 - 24.0) | 24.0 (20.0 - 24.6) | 21.8 (19.7 - 24.0) |  __0.028__  |\n|__baseline_CLCR__        |     48 (21 - 84)     |    50 (24 - 80)    |    40 (17 - 86)    |   70 (41 - 104)    |    60 (27 - 95)    |    29 (14 - 54)    |    35 (17 - 67)    | __<0.001__  |\n|__dept_ER__              |      140 (17%)       |      7 (5.6%)      |      9 (12%)       |      67 (37%)      |      15 (13%)      |      16 (16%)      |      26 (12%)      | __<0.001__  |\n|__dept_ICU__             |      390 (48%)       |     10 (8.0%)      |      23 (30%)      |      73 (41%)      |      42 (36%)      |      77 (77%)      |     165 (75%)      | __<0.001__  |\n|__baseline_HGB__         |    102 (89 - 120)    |   105 (91 - 124)   |   99 (83 - 118)    |   105 (89 - 123)   |   100 (88 - 118)   |   99 (89 - 116)    |   104 (91 - 120)   |     0.2     |\n|__baseline_WBC__         |     12 (8 - 17)      |    11 (7 - 16)     |    11 (7 - 17)     |    12 (8 - 18)     |    11 (7 - 15)     |    12 (8 - 18)     |    13 (9 - 18)     |  __0.023__  |\n|__baseline_PLT__         |   206 (143 - 288)    |  195 (139 - 247)   |  234 (160 - 318)   |  207 (129 - 293)   |  225 (127 - 310)   |  172 (122 - 245)   |  225 (161 - 299)   | __<0.001__  |\n|__LZD_duration__         |   9.0 (6.0 - 14.0)   |  8.0 (6.0 - 13.0)  | 10.0 (6.0 - 14.0)  | 10.0 (6.0 - 14.0)  |  9.0 (6.0 - 12.0)  | 11.0 (6.0 - 15.0)  |  9.0 (6.0 - 12.0)  |     0.3     |\n|__invasive_ETI__         |      386 (47%)       |      63 (50%)      |      30 (39%)      |     111 (62%)      |      49 (42%)      |      48 (48%)      |      85 (39%)      | __<0.001__  |\n|__invasive_CVC__         |      423 (52%)       |      75 (60%)      |      30 (39%)      |      99 (55%)      |      48 (41%)      |      50 (50%)      |     121 (55%)      |  __0.008__  |\n|__invasive_IHD__         |      111 (14%)       |      17 (14%)      |      16 (21%)      |      9 (5.0%)      |       0 (0%)       |      27 (27%)      |      42 (19%)      | __<0.001__  |\n|__invasive_CRRT__        |      147 (18%)       |      17 (14%)      |      9 (12%)       |      52 (29%)      |      5 (4.3%)      |      20 (20%)      |      44 (20%)      | __<0.001__  |\n|__comorb_HTN__           |      333 (41%)       |      42 (34%)      |      31 (40%)      |      49 (27%)      |      28 (24%)      |      59 (59%)      |     124 (57%)      | __<0.001__  |\n|__comorb_DM__            |      222 (27%)       |      28 (22%)      |      24 (31%)      |      28 (16%)      |      27 (23%)      |      31 (31%)      |      84 (38%)      | __<0.001__  |\n|__comorb_HF__            |      225 (28%)       |      55 (44%)      |      11 (14%)      |     14 (7.8%)      |      7 (6.0%)      |      70 (70%)      |      68 (31%)      | __<0.001__  |\n|__comorb_angina__        |      32 (3.9%)       |       0 (0%)       |       0 (0%)       |      1 (0.6%)      |       0 (0%)       |      13 (13%)      |     18 (8.2%)      | __<0.001__  |\n|__comorb_cirr__          |      48 (5.9%)       |      6 (4.8%)      |      1 (1.3%)      |     10 (5.6%)      |      5 (4.3%)      |      12 (12%)      |     14 (6.4%)      |    0.078    |\n|__comorb_COPD__          |      39 (4.8%)       |      3 (2.4%)      |       0 (0%)       |      2 (1.1%)      |      2 (1.7%)      |      9 (9.0%)      |      23 (11%)      | __<0.001__  |\n|__comorb_CVA__           |       93 (11%)       |      19 (15%)      |      11 (14%)      |      6 (3.4%)      |      4 (3.4%)      |      16 (16%)      |      37 (17%)      | __<0.001__  |\n|__comorb_MI__            |      20 (2.5%)       |     10 (8.0%)      |      3 (3.9%)      |      2 (1.1%)      |       0 (0%)       |      1 (1.0%)      |      4 (1.8%)      | __<0.001__  |\n|__comorb_K__             |      67 (8.2%)       |      5 (4.0%)      |      5 (6.5%)      |      8 (4.5%)      |      6 (5.2%)      |      11 (11%)      |      32 (15%)      | __<0.001__  |\n|__comorb_hematological__ |      46 (5.6%)       |      9 (7.2%)      |      12 (16%)      |     10 (5.6%)      |      5 (4.3%)      |      8 (8.0%)      |      2 (0.9%)      | __<0.001__  |\n|__comorb_hema__          |      61 (7.5%)       |      13 (10%)      |      17 (22%)      |     14 (7.8%)      |      2 (1.7%)      |      13 (13%)      |      2 (0.9%)      | __<0.001__  |\n|__infect_sepsis__        |      134 (16%)       |     10 (8.0%)      |      14 (18%)      |     16 (8.9%)      |      15 (13%)      |      44 (44%)      |      35 (16%)      | __<0.001__  |\n|__infect_CAP__           |      118 (14%)       |      7 (5.6%)      |      6 (7.8%)      |     11 (6.1%)      |      1 (0.9%)      |      26 (26%)      |      67 (31%)      | __<0.001__  |\n|__infect_HAP__           |      375 (46%)       |      38 (30%)      |      33 (43%)      |      93 (52%)      |      59 (51%)      |      52 (52%)      |     100 (46%)      |  __0.003__  |\n|__infect_SSTI__          |      133 (16%)       |      33 (26%)      |      34 (44%)      |      1 (0.6%)      |      4 (3.4%)      |      23 (23%)      |      38 (17%)      | __<0.001__  |\n|__infect_CNS__           |      68 (8.3%)       |       0 (0%)       |      5 (6.5%)      |      24 (13%)      |      20 (17%)      |      4 (4.0%)      |     15 (6.8%)      | __<0.001__  |\n|__infect_IAI__           |      50 (6.1%)       |      8 (6.4%)      |      8 (10%)       |      1 (0.6%)      |      2 (1.7%)      |      12 (12%)      |     19 (8.7%)      | __<0.001__  |\n|__infect_UTI__           |      53 (6.5%)       |      6 (4.8%)      |      8 (10%)       |     10 (5.6%)      |      5 (4.3%)      |      4 (4.0%)      |     20 (9.1%)      |     0.2     |\n|__infect_BJI__           |      11 (1.3%)       |      3 (2.4%)      |       0 (0%)       |       0 (0%)       |      2 (1.7%)      |      1 (1.0%)      |      5 (2.3%)      |     0.2     |\n|__infect_septicemia__    |      237 (29%)       |      35 (28%)      |      24 (31%)      |      57 (32%)      |      60 (52%)      |      7 (7.0%)      |      54 (25%)      | __<0.001__  |\n|__comed_aspirin__        |      47 (5.8%)       |      8 (6.4%)      |      9 (12%)       |      3 (1.7%)      |       0 (0%)       |      5 (5.0%)      |      22 (10%)      | __<0.001__  |\n|__comed_diclofenac__     |      27 (3.3%)       |      24 (19%)      |       0 (0%)       |       0 (0%)       |      1 (0.9%)      |       0 (0%)       |      2 (0.9%)      | __<0.001__  |\n|__comed_ibuprofen__      |      26 (3.2%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |      2 (1.7%)      |       0 (0%)       |      24 (11%)      | __<0.001__  |\n|__comed_paracetamol__    |      357 (44%)       |      66 (53%)      |       0 (0%)       |      92 (51%)      |      69 (59%)      |      47 (47%)      |      83 (38%)      | __<0.001__  |\n|__comed_penicillin__     |      123 (15%)       |       0 (0%)       |      5 (6.5%)      |      34 (19%)      |      19 (16%)      |      17 (17%)      |      48 (22%)      | __<0.001__  |\n|__comed_cepha__          |      208 (25%)       |     12 (9.6%)      |      10 (13%)      |      36 (20%)      |      33 (28%)      |      11 (11%)      |     106 (48%)      | __<0.001__  |\n|__comed_carbapenem__     |      588 (72%)       |      52 (42%)      |      46 (60%)      |     158 (88%)      |      78 (67%)      |      80 (80%)      |     174 (79%)      | __<0.001__  |\n|__comed_cotrimoxazol__   |      67 (8.2%)       |       0 (0%)       |      5 (6.5%)      |      20 (11%)      |      14 (12%)      |      9 (9.0%)      |     19 (8.7%)      |  __0.007__  |\n|__comed_vancomycin__     |      67 (8.2%)       |      8 (6.4%)      |      3 (3.9%)      |     10 (5.6%)      |      22 (19%)      |      3 (3.0%)      |     21 (9.6%)      | __<0.001__  |\n|__comed_levofloxacin__   |      250 (31%)       |      27 (22%)      |      6 (7.8%)      |      24 (13%)      |      20 (17%)      |      34 (34%)      |     139 (63%)      | __<0.001__  |\n|__comed_teicoplanin__    |      37 (4.5%)       |       0 (0%)       |       0 (0%)       |      7 (3.9%)      |      2 (1.7%)      |       0 (0%)       |      28 (13%)      | __<0.001__  |\n|__comed_ethambutol__     |       8 (1.0%)       |       0 (0%)       |       0 (0%)       |      2 (1.1%)      |      6 (5.2%)      |       0 (0%)       |       0 (0%)       | __<0.001__  |\n|__comed_pyrazinamid__    |      12 (1.5%)       |       0 (0%)       |       0 (0%)       |      5 (2.8%)      |      7 (6.0%)      |       0 (0%)       |       0 (0%)       | __<0.001__  |\n|__comed_rifampin__       |      15 (1.8%)       |       0 (0%)       |       0 (0%)       |      5 (2.8%)      |      9 (7.8%)      |      1 (1.0%)      |       0 (0%)       | __<0.001__  |\n|__comed_heparin__        |      207 (25%)       |     12 (9.6%)      |      2 (2.6%)      |      74 (41%)      |      24 (21%)      |      33 (33%)      |      62 (28%)      | __<0.001__  |\n|__comed_clopidogrel__    |      40 (4.9%)       |      7 (5.6%)      |      4 (5.2%)      |      1 (0.6%)      |       0 (0%)       |      8 (8.0%)      |     20 (9.1%)      | __<0.001__  |\n|__comed_enoxaparin__     |      352 (43%)       |      33 (26%)      |      13 (17%)      |     119 (66%)      |      44 (38%)      |      40 (40%)      |     103 (47%)      | __<0.001__  |\n|__comed_dexamethason__   |      106 (13%)       |       0 (0%)       |       0 (0%)       |      75 (42%)      |      20 (17%)      |      2 (2.0%)      |      9 (4.1%)      | __<0.001__  |\n|__comed_amiodaron__      |      36 (4.4%)       |      8 (6.4%)      |       0 (0%)       |     14 (7.8%)      |      5 (4.3%)      |      4 (4.0%)      |      5 (2.3%)      |  __0.026__  |\n|__comed_furosemid__      |      436 (53%)       |      72 (58%)      |      15 (19%)      |      81 (45%)      |      49 (42%)      |      71 (71%)      |     148 (68%)      | __<0.001__  |\n|__comed_haloperidol__    |      53 (6.5%)       |      3 (2.4%)      |      4 (5.2%)      |      21 (12%)      |      4 (3.4%)      |      5 (5.0%)      |     16 (7.3%)      |  __0.015__  |\n|__comed_valproic__       |      32 (3.9%)       |       0 (0%)       |      1 (1.3%)      |     10 (5.6%)      |      5 (4.3%)      |      3 (3.0%)      |     13 (5.9%)      |  __0.029__  |\n|__comed_aceclofenac__    |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_naproxen__       |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_daptomycin__     |       1 (0.1%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |      1 (0.9%)      |       0 (0%)       |       0 (0%)       |     0.4     |\n|__comed_cetirizin__      |       6 (0.7%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |      6 (2.7%)      |  __0.015__  |\n|__comed_simvas__         |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_bisoprolol__     |       6 (0.7%)       |      4 (3.2%)      |       0 (0%)       |      1 (0.6%)      |      1 (0.9%)      |       0 (0%)       |       0 (0%)       |  __0.029__  |\n|__comed_diltiazem__      |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_eptifibatid__    |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_quinidin__       |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_carbamazepin__   |       8 (1.0%)       |       0 (0%)       |       0 (0%)       |      7 (3.9%)      |       0 (0%)       |       0 (0%)       |      1 (0.5%)      |  __0.003__  |\n|__comed_phenytoin__      |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_mirtazapin__     |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_quetiapin__      |       4 (0.5%)       |      1 (0.8%)      |      1 (1.3%)      |       0 (0%)       |       0 (0%)       |       0 (0%)       |      2 (0.9%)      |     0.5     |\n|__comed_ondansetron__    |       6 (0.7%)       |      2 (1.6%)      |      1 (1.3%)      |       0 (0%)       |      3 (2.6%)      |       0 (0%)       |       0 (0%)       |  __0.016__  |\n|__comed_palonosetron__   |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_oseltamivir__    |       2 (0.2%)       |      1 (0.8%)      |      1 (1.3%)      |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |    0.14     |\n|__comed_quinin__         |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_pembrolizumab__  |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_trastuzumab__    |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_atezolizumab__   |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_durvalumab__     |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_IVIG__           |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_tacrolimus__     |       1 (0.1%)       |      1 (0.8%)      |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |     0.5     |\n|__comed_fluorouracil__   |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_irinotecan__     |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_leucovorin__     |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__comed_oxaliplatin__    |        0 (0%)        |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |       0 (0%)       |             |\n|__flag_ADR_TP_ID__       |      264 (32%)       |      34 (27%)      |      22 (29%)      |      59 (33%)      |      35 (30%)      |      38 (38%)      |      76 (35%)      |     0.5     |\n|__ADR_CTCAE_max__        |                      |                    |                    |                    |                    |                    |                    | __<0.001__  |\n|1                        |       85 (32%)       |      11 (32%)      |      9 (41%)       |      17 (29%)      |      7 (20%)       |      7 (18%)       |      34 (45%)      |             |\n|2                        |       78 (30%)       |      10 (29%)      |      6 (27%)       |      12 (20%)      |      6 (17%)       |      17 (45%)      |      27 (36%)      |             |\n|3                        |       49 (19%)       |      4 (12%)       |      3 (14%)       |      17 (29%)      |      7 (20%)       |      6 (16%)       |      12 (16%)      |             |\n|4                        |       52 (20%)       |      9 (26%)       |      4 (18%)       |      13 (22%)      |      15 (43%)      |      8 (21%)       |      3 (3.9%)      |             |\n|__ADR_onset_first__      |   4.0 (2.0 - 10.0)   |  2.0 (1.0 - 9.8)   |  3.5 (2.0 - 7.8)   |  4.0 (2.0 - 9.0)   |  6.0 (2.5 - 11.0)  |  4.0 (2.0 - 9.0)   |  6.0 (2.0 - 11.0)  |    0.15     |\n|__ADR_PLT_ratio__        |  0.36 (0.22 - 0.52)  | 0.55 (0.26 - 0.64) | 0.39 (0.21 - 0.58) | 0.37 (0.26 - 0.50) | 0.30 (0.16 - 0.45) | 0.36 (0.20 - 0.48) | 0.35 (0.25 - 0.50) |    0.077    |\n\n\n:::\n:::\n\n\n\n\n\n:::\n\n## Model Performance\n\n\n\n\n\n::: {.cell}\n\n```{.r .cell-code .hidden}\nload(\"data/model-performance/apparent-performance-metrics.rda\")\nload(\"data/model-performance/corrected-performance-metrics.rda\")\nload(\"data/model-performance/fold-performance-metrics.rda\")\nload(\"data/model-performance/cross-performance-metrics.rda\")\n\ndata_list <- list(\n  apparent_performance_metrics,\n  corrected_performance_metrics,\n  fold_performance_metrics\n)\nperformance_type_list <- c(\"Apparent\", \"Bootstrap\", \"K-fold\")\ninitial_string_list <- c(\"apparent_\", \"corrected_\", \"mean_fold_\")\n\nreformat_performance_metrics <- function(data, type, string) {\n  data |> \n    mutate(\n    performance_type = type\n  ) |>\n  rename_with(~ str_replace(., string, \"\")) |>\n  select(performance_type, everything())\n}\n\nperformance_metrics <- pmap(\n  list(data_list, performance_type_list, initial_string_list), \n  reformat_performance_metrics\n) |> bind_rows()\n\nperformance_metrics |> knitr::kable()\n```\n\n::: {.cell-output-display}\n\n\n|performance_type |   C_index| calibration_intercept| calibration_slope|\n|:----------------|---------:|---------------------:|-----------------:|\n|Apparent         | 0.7860397|             0.0000000|         1.0000000|\n|Bootstrap        | 0.7534568|            -0.0188899|         0.8139667|\n|K-fold           | 0.7519437|            -0.0261553|         0.8719934|\n\n\n:::\n:::",
    "supporting": [
      "index_files"
    ],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": null,
    "postProcess": false
  }
}